Catequentinib for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors. The phase 1b part will identify doses that can be given safely based on side effects during the first treatment cycle. The phase 2a part will estimate whether the treatments shrink non-brain tumors or keep glioblastoma from worsening for at least 6 months.
The study is open label, which means participants and study investigators will know which treatment is given. Tumor response will be assessed with RECIST version 1.1. The study will also evaluate how the investigational drugs move through the body, the duration of tumor response, progression-free survival, overall survival, and treatment safety.
Who Is on the Research Team?
Judy Chen
Principal Investigator
Advenchen Pharmaceuticals, LLC.
Carlos K Matsuoka, MD
Principal Investigator
UT MD Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic endometrial, ovarian, soft tissue sarcoma, glioblastoma, or other solid tumors. Participants should have cancer that has spread or not responded to standard treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- AL58805
- Catequentinib Hydrochloride (AL3818)
- Lomustine (CCNU)
- Temozolomide (TMZ)
Trial Overview
Researchers are testing catequentinib hydrochloride (AL3818) alone or combined with AL58805, temozolomide (TMZ), or lomustine (CCNU). The study aims to find safe doses and see if these drugs can shrink tumors or slow their growth.
How Is the Trial Designed?
7
Treatment groups
Experimental Treatment
This cohort evaluates the safety and efficacy of AL3818 (RCD-B1 and RCD-B2 from Cohort B1 and B2) qd/4 days on, 3 days off) in combination with Temozolomide (150 mg/m², 5 days on/23 days off) all for 28 days per cycle for up to 6 cycles of Temozolomide, or CCNU (90 mg/m²) in a 8-week cycle for up to 6 cycles of CCNU to PD or intolerability for ≥ 2nd line treatment (age: ≥ 18) GBM patients. Enrollment is at n=17 individually for Temozolomide or CCNU which is sequentially enrolled at PI's discretion.
This cohort evaluates the safety and efficacy of AL3818 + AL58805 at RP2D (determined from Cohort A2) in patients with advanced endometrial, LGSOC or STS cancer (≥2nd-line, age ≥18). Enrollment n=17 each indication, Optional biomarker research may be included to identify mutations of PIK3CA, PTEN, ARID1A and homologous recombination deficiency. LGSOC patient can use AL3818 for1st line treatment at PI's discretion.
This cohort evaluates the preliminary efficacy and safety of AL3818 monotherapy at the RP2D (determined from Cohort A, 4 days on/3 days off in 28-day cycles) in patients with advanced endometrial, LGSOC cancer (≥2nd-line, age ≥18) with TP53 mutated adenocarcinoma, TP53 carcinosarcoma and TP53 wild type. Treatment continues until disease progression (PD) or intolerability (n=17 for each TP53 and LGSOC group). LGSOC patient can use AL3818 for1st line treatment at PI's discretion.
This cohort evaluates the safety and tolerability of AL3818 12mg (or 10 mg), 4 days on/3 days off (if passed DLT) in combination with Temozolomide (150 mg/m², 5 days on/23 days off) in a 28-day cycle for up to 6 cycles of Temozolomide, or CCNU (90 mg/m²) in a 8-week cycle for up to 6 cycles of CCNU for glioblastoma (GBM) patients. A 3+3 DLT assessment will determine the recommended combination dose (RCD) with RCD-B1 for Temozolomide or RCD-B2 for CCNU respectively. Temozolomide or CCNU is sequentially enrolled at PI's discretion based on patients meeting eligibility criteria. If DLT is observed in this combination therapy, the AL3818 dose will be further reduced to next -2 mg level. Patients from Cohort B1 without DLTs in the first cycle (28 days for Temozolomide or 56 days for CCNU) may transition to this Cohort B2. RCD-B1 and RCD-B2 will be used in phase 2a study.
This cohort evaluates the safety and tolerability of AL3818 monotherapy (12mg, 4 days on/3 days off) for glioblastoma (GBM) patients. A 3+3 design is used to assess dose-limiting toxicities (DLTs), de-escalate to 10 mg if DLT observed. If no DLT observed, Patients will go next cohort P1b.2-B2 for combination study.
This cohort evaluates the safety and tolerability of oral AL3818 (12mg or 10mg, 4 days on/3 days off, based on above RP2D-2mg) in combination with AL58805 (10 mg) in a 28-day per cycle for patients with STS or Endometrial patients. A 3+3 design is used to assess dose-limiting toxicities (DLTs), escalate AL58805 to 20mg if no DLT or deescalate AL3818 to 10 mg if DLT observed, to determine the recommended combination therapy Phase II dose (RP2D). LGSOC patient can use AL3818 for1st line treatment at PI's discretion.
This cohort evaluates the safety and tolerability of oral AL3818 monotherapy (12 mg, 4 days on/3 days off) in a 28-day per cycle for patients with advanced solid tumors such as NSCLC, SCLC, STS, Thyroid, Endometrial, LGSOC, Breast cancer patients who require ≥2nd-line therapy or have no standard of care (SOC) treatment options (age ≥18). A 3+3 design is used to assess dose-limiting toxicities (DLTs), escalate to 14 mg if no DLT or de-escalate to 10 mg if DLT observed, to determine the recommended monotherapy Phase II dose (RP2D). LGSOC patient can use AL3818 for1st line treatment at PI's discretion.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Advenchen Pharmaceuticals, LLC.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.